Cogent Biosciences (COGT) director takes options in lieu of cash
Cogent Biosciences director Karen Jean Ferrante received a grant of 627 stock options on July 1, 2026, as compensation instead of cash fees. These options have an exercise price of $38.48 per share and expire on July 1, 2036. This grant was part of the company's non-employee director compensation plan, aligning her interests with the company's long-term performance.
Enterprise value to revenue forward of Cogent Biosciences, Inc. – NASDAQ:COGT
This article provides forward-looking enterprise value to revenue data for Cogent Biosciences, Inc. (NASDAQ: COGT). It appears to be a financial data point from TradingView, offering a snapshot of a specific valuation metric. The content is very brief and seems to be a data element rather than a traditional analytical article.
Price to earnings forward of Cogent Biosciences, Inc. – NASDAQ:COGT
This article provides financial information for Cogent Biosciences, Inc. (NASDAQ: COGT) focusing on its price to earnings forward. It is presented in a data-centric format from TradingView, including market data and reference data from various financial service providers.
3 Reasons Cogent Biosciences (COGT) Looks Pricey After Its FDA Filing
Cogent Biosciences (COGT) filed a New Drug Application with the FDA for bezuclastinib, leading to a significant rally in its share price. Despite strong performance and positive trial data, the stock appears pricey with a price-to-book ratio of 12.1x, significantly above the broader biotech industry average of 2.7x. Investors are valuing future pipeline success over current financials, as the company still reports a net loss.
COGT - Cogent Biosciences Inc Forecast, Target Price
This article provides a detailed financial overview and forecast for Cogent Biosciences Inc (COGT). It includes key metrics such as market capitalization, income, sales, P/E ratios, and various performance indicators. The data also presents analyst recommendations and a target price for the stock.
Cogent Biosciences (COGT) Submits NDA to FDA for Bezuclastinib
Cogent Biosciences has submitted a New Drug Application (NDA) to the FDA for bezuclastinib, a treatment for Advanced Systemic Mastocytosis, supported by APEX clinical trial findings. Despite this milestone, the company faces challenges indicated by its low GF Score™ of 25/100 and significant insider selling amounting to $242.6 million in the past three months. While potential approval offers opportunities, investors are advised to proceed with caution due to valuation concerns and insider activity.
How (COGT) Movements Inform Risk Allocation Models
This article analyzes Cogent Biosciences Inc. (NASDAQ: COGT) using AI models, indicating a strong overweight bias across all time horizons. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. Key findings highlight a 70.2:1 risk-reward short setup and specific entry/target/stop-loss levels.
Cogent seeks FDA approval for rare blood disease drug
Cogent Biosciences has submitted a New Drug Application (NDA) to the FDA for its drug bezuclastinib, targeting advanced systemic mastocytosis (AdvSM). This submission is supported by positive data from the APEX pivotal trial, which showed high objective response rates and a well-tolerated safety profile. The company anticipates potential FDA approval for bezuclastinib across multiple indications, including AdvSM, later in 2026.
Cogent Biosciences Announces Submission of New Drug
Cogent Biosciences has submitted a New Drug Application (NDA) to the FDA for bezuclastinib to treat Advanced Systemic Mastocytosis (AdvSM), based on positive data from the APEX pivotal trial. The company expects the drug to receive its first approvals later in 2026, building on strong clinical benefits observed in AdvSM patients with a well-tolerated safety profile. This marks the third NDA submission for bezuclastinib within six months, with other reviews for PEAK and SUMMIT trials also underway.
Why Cogent Biosciences (COGT) Is Up 6.7% After Russell Index Removal Reshapes Its Investor Base
Cogent Biosciences (COGT) saw its stock rise 6.7% after its removal from several Russell indices, including the Russell 3000E and Russell 2000 Value. This removal is expected to reshape the company's investor base by shifting out passive institutional money, potentially impacting liquidity and cost of equity. Despite these changes, the company's core investment narrative remains focused on the success of its drug bezuclastinib and its earlier-stage pipeline, with upcoming FDA reviews and data readouts.
Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Value Benchmark Index
Cogent Biosciences, Inc. (NasdaqGS:COGT) has been removed from the Russell Microcap Value Benchmark Index. This news follows several other announcements regarding the company's exclusion from various Russell indices on June 29th and 28th, 2026. Despite these index changes, the company recently submitted a New Drug Application for Bezuclastinib and announced positive preclinical and clinical data for its treatments.
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Ros Matthew
This document from Cogent Biosciences is a Statement of Changes in Beneficial Ownership of Securities, specifically Form 4, related to Director Ros Matthew. It details how the beneficial ownership of Cogent Biosciences securities by Ros Matthew has changed.
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Robbins Andrew R
This document from Cogent Biosciences is a Statement of changes in beneficial ownership of securities (Form 4). It concerns Officer Robbins Andrew R, indicating a change in their security holdings.
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Shegog Todd
This document, titled "4: Statement of changes in beneficial ownership of securities-Director Shegog Todd," indicates a formal filing regarding changes in the beneficial ownership of securities for Todd Shegog, a Director at Cogent Biosciences. Such statements are routinely filed to disclose insider trading activities.
COGT Forecast — Price Target — Prediction for 2027
This article provides a forecast for Cogent Biosciences, Inc. (COGT) stock, including analyst price targets, historical performance, and financial data. Analysts have a 1-year price forecast, with a max estimate of $72.00 and a min estimate of $35.00. The company's stock has seen significant growth over the past year, and its next earnings report is scheduled for August 11, 2026.
Cogent Biosciences, Inc. Actuals & Estimates (NASDAQ:COGT)
This article provides current stock performance data and financial estimates for Cogent Biosciences, Inc. (COGT). It covers recent stock price movements, analyst forecasts, historical highs and lows, market capitalization, and upcoming earnings reports, along with financial metrics like revenue and net income.
COGT Forecast — Price Target — Prediction for 2027
This article provides a forecast for Cogent Biosciences, Inc. (COGT) stock, including analyst price targets and ratings. It details the company's past earnings and revenue, future earnings report dates, and financial statistics. The piece also answers frequently asked questions about COGT's stock ticker, dividend policy, employee count, and how to purchase shares.
Cogent (COGT) Presents Preclinical Data for Novel JAK2 Inhibitor CGT1145 at 2026 EHA Congress
Cogent Biosciences Inc. (NASDAQ: COGT) presented promising preclinical data for its novel JAK2 V617F inhibitor, CGT1145, at the 2026 EHA Congress. This candidate, designed to be a best-in-class therapy, shows high selectivity and oral bioavailability, aiming to treat myeloproliferative neoplasms/MPNs more effectively with reduced side effects. The company plans to submit an Investigational New Drug (IND) application later in 2026, marking a significant step in developing precision therapies for genetically defined diseases.
Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?
Cogent Biosciences (COGT) has unveiled early-stage preclinical data for its experimental drug CGT1145, presented as a potentially more precise and better-tolerated treatment for certain rare blood cancers. Lab results indicate CGT1145 is over 100-fold selective for a specific gene mutation (JAK2 V617F) associated with blood cancers, aiming to avoid side effects seen with current treatments. The company plans to file an Investigational New Drug application with the FDA later this year based on these robust findings.
New Bezuclastinib and JAK2 Data Could Be A Game Changer For Cogent Biosciences (COGT)
Cogent Biosciences presented new data for bezuclastinib in advanced systemic mastocytosis and preclinical results for CGT1145 (a JAK2 V617F inhibitor) at the 2026 European Hematology Association Congress. These findings support bezuclastinib's potential as a multi-indication therapy and CGT1145's promise in MPN, reinforcing Cogent's focus on genetically defined hematologic diseases. While the data strengthens the investment thesis, investors should also consider potential overvaluation, regulatory timelines, and funding needs for the expanding pipeline.
New Bezuclastinib and JAK2 Data Could Be A Game Changer For Cogent Biosciences (COGT)
Cogent Biosciences recently presented updated APEX trial data for bezuclastinib in advanced systemic mastocytosis and preclinical results for its JAK2 V617F inhibitor CGT1145. These findings reinforce the company's focus on genetically defined hematologic diseases, with bezuclastinib showing strong efficacy and CGT1145 offering potential for mutation-selective targeting in myeloproliferative neoplasms. While these data strengthen the investment narrative for Cogent, investors should also consider the potential for future dilution and the company's ongoing losses, as reflected in a fair value estimate of US$54.25 per share.
COGT - Cogent Biosciences Inc Stock Price and Quote
This article provides a detailed stock price and quote for Cogent Biosciences Inc. (COGT), including financial figures, insider ownership, analyst ratings, and recent news. It highlights the company's focus on developing precision therapies for genetically defined diseases and its key drug candidate, bezuclastinib, for various conditions like gastrointestinal stromal tumors (GIST) and systemic mastocytosis.
Cogent Biosciences Inc (COGT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Cogent Biosciences Inc (COGT) stock information, including its dividend history and stock split events. It notes that COGT has not distributed any dividends in the past five years but details multiple merger-related stock splits that occurred on November 6, 2020. The current stock price and market capitalization are also presented.
Cogent Biosciences (COGT) Stock Can APEX Trial Progress Justify A 10.6x P B Ratio
Cogent Biosciences (COGT) is under scrutiny after releasing updated APEX trial data for bezuclastinib and preclinical results for CGT1145. Despite a significant 4.7x return over the past year, the stock trades at a P/B ratio of 10.6x, which is considered expensive against the US Biotechs industry average but cheaper than some close comparables. The article questions whether this valuation is justified given the company's lack of revenue and ongoing losses, highlighting both optimism and caution for investors.
Cogent Biosciences (COGT) Stock Can APEX Trial Progress Justify A 10.6x P B Ratio
Cogent Biosciences (COGT) is under scrutiny after releasing updated APEX trial data and preclinical results for its drugs. Despite a significant stock rally and a 10.6x Price-to-Book ratio, the article questions if this valuation is justified given the company's lack of revenue and ongoing losses, highlighting both its expensive valuation compared to the broader biotech industry and its relatively good value against some closer peers. The analysis suggests that while the market is pricing COGT above the sector average, it's at a discount to some peer valuations.
Cogent Biosciences Inc (COGT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Cogent Biosciences Inc (COGT), focusing on business segments, regional revenue, and profit contribution for FY2021. However, it explicitly states that relevant data for these categories have not yet been disclosed by the company. As a result, the article indicates 0.00 for revenue and proportion for the United States, and generally notes the absence of detailed segment or regional data.
Stifel reiterates Cogent stock Buy rating after trial data By Investing.com
Stifel reiterated a Buy rating and a $45.00 price target for Cogent Biosciences (NASDAQ:COGT) following updated clinical results from the APEX trial for bezuclastinib. Despite its current unprofitability, Cogent saw a 367% gain in its stock over the past year and plans to submit a New Drug Application for bezuclastinib in June 2026. Other firms like Raymond James and H.C. Wainwright also maintain Buy ratings, citing strong trial data and financial positioning.
Cogent Biosciences (COGT) Is Up 6.7% After Positive PEAK Trial Data and FDA Priority Review - What's Changed
Cogent Biosciences (COGT) saw a 6.7% increase in its stock price following positive data from its PEAK Phase 3 trial and subsequent FDA Priority Review for bezuclastinib in combination with sunitinib for gastrointestinal stromal tumors. The trial showed significant improvements in progression-free survival and response rates. This success is expected to reshape Cogent Biosciences' investment narrative, emphasizing bezuclastinib's potential as a multi-indication commercial franchise despite current losses.
Cogent Biosciences (COGT) Is Up 6.7% After Positive PEAK Trial Data and FDA Priority Review - What's Changed
Cogent Biosciences (COGT) shares increased by 6.7% following positive Phase 3 PEAK trial data for bezuclastinib in gastrointestinal stromal tumors (GIST) and subsequent FDA Priority Review. The drug, in combination with sunitinib, showed significant improvement in progression-free survival and response rates. This success is seen as strengthening Cogent's investment narrative, though the company still faces challenges regarding funding and potential dilution, with a PDUFA date set for November 30, 2026.
Cogent Biosciences unveils pivotal APEX trial data at EHA 2026
Cogent Biosciences announced positive detailed clinical results from its pivotal APEX trial for bezuclastinib in advanced systemic mastocytosis at the EHA 2026 Congress. The data showed rapid, deep, and durable clinical improvements, with robust objective response rates and significant reductions in mast cell burden. The company plans to submit a New Drug Application (NDA) for bezuclastinib to the FDA before the end of June 2026.
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association Congress
Cogent Biosciences presented encouraging preclinical data for CGT1145, their novel JAK2 V617F mutant-selective inhibitor, at the 2026 European Hematology Association (EHA) Congress. This inhibitor shows potential as a best-in-class therapy for myeloproliferative neoplasms by selectively targeting the disease's underlying mutation while minimizing off-target hematological effects. The company is on track to submit an Investigational New Drug (IND) application for CGT1145 in 2026.
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association Congress
Cogent Biosciences has released detailed and updated clinical results from its APEX pivotal trial of bezuclastinib for advanced systemic mastocytosis (AdvSM), demonstrating rapid and deep clinical benefit. The data, including an objective response rate of 65% (mIWG criteria) and 81% (PPR criteria), show bezuclastinib's powerful effect on mast cell burden and a favorable safety profile. The company plans to submit the APEX NDA in June 2026 and aims to launch bezuclastinib later this year following FDA approval for both systemic mastocytosis and GIST.
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
Cogent Biosciences announced promising preclinical data for CGT1145, their novel JAK2 V617F mutant-selective inhibitor, at the 2026 European Hematology Association (EHA) Congress. This inhibitor demonstrates high selectivity and potential to address the underlying mutational driver of myeloproliferative neoplasms while mitigating off-target effects. The company plans to submit an Investigational New Drug (IND) application for CGT1145 in 2026, aiming for better hematologic tolerability and molecular remission.
Cogent Biosciences Announces Preclinical Data from Novel
Cogent Biosciences announced promising preclinical data for CGT1145, its novel JAK2 V617F mutant-selective inhibitor, at the 2026 European Hematology Association (EHA) Congress. The data highlighted CGT1145's potential as a best-in-class treatment, showing improved selectivity compared to current JAK inhibitors and the ability to address the underlying mutational driver of myeloproliferative neoplasms. The company plans to submit an Investigational New Drug (IND) application for CGT1145 in 2026.
Experimental JAK2 inhibitor targets mutation in most polycythemia vera cases
Cogent Biosciences announced promising preclinical data for its novel JAK2 V617F mutant-selective inhibitor, CGT1145, at the 2026 European Hematology Association (EHA) Congress. The drug candidate demonstrated high selectivity and oral bioavailability, targeting the mutation prevalent in most polycythemia vera cases and a significant portion of myelofibrosis/essential thrombocythemia patients. An Investigational New Drug (IND) application for CGT1145 is planned for 2026, advancing Cogent's pipeline for genetically defined diseases.
Cogent Biosciences Announces Detailed Data from APEX
Cogent Biosciences announced detailed data from its APEX pivotal trial of bezuclastinib for advanced systemic mastocytosis (AdvSM) at the 2026 European Hematology Association (EHA) Congress. The data shows bezuclastinib achieved rapid and deep clinical benefits, with an objective response rate of 65% per mIWG criteria and 81% per PPR criteria, demonstrating a favorable safety profile. The company plans to submit the APEX NDA in June 2026 and expects to launch bezuclastinib later this year following FDA approval for both systemic mastocytosis and GIST.
Experimental drug cuts mast cell disease markers in most AdvSM patients
Cogent Biosciences announced detailed results from its APEX pivotal trial for bezuclastinib in advanced systemic mastocytosis (AdvSM), showing a 65% objective response rate (ORR) per mIWG criteria and significant reductions in mast cell burden. The drug also demonstrated a favorable safety profile and prolonged progression-free and overall survival rates. Cogent plans to submit a New Drug Application (NDA) for bezuclastinib in June 2026, aiming for commercial launch later in the year, following FDA approval.
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
Cogent Biosciences announced preclinical data for its novel JAK2 V617F mutant-selective inhibitor, CGT1145, at the 2026 European Hematology Association (EHA) Congress. The data highlighted CGT1145's potential as a best-in-class therapy with improved selectivity and the ability to address the underlying mutational driver of myeloproliferative neoplasms. The company plans to submit an Investigational New Drug application for CGT1145 in 2026.
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
Cogent Biosciences announced detailed results from its APEX pivotal trial of bezuclastinib for advanced systemic mastocytosis (AdvSM), showing a 65% objective response rate by mIWG criteria and 81% by PPR criteria. The drug also demonstrated significant reductions in mast cell burden and a favorable safety profile. The company plans to submit the APEX NDA in June 2026 and expects to launch bezuclastinib later in the year for both systemic mastocytosis and GIST.
Cogent Biosciences (COGT) director Arlene Morris receives grant of 17,901 stock options
Cogent Biosciences director Arlene Morris was granted 17,901 stock options with an exercise price of $31.98 per share, expiring on June 9, 2036. This grant is considered compensation, not an open-market transaction, and the options will vest fully on the earlier of one year from the grant date or the 2027 Annual Meeting of Stockholders, provided she continues her service to the company. After this transaction, Morris directly holds stock options for 17,901 shares.
Director at Cogent Biosciences (NASDAQ: COGT) receives 17,901 stock options
Todd Shegog, a director at Cogent Biosciences (NASDAQ: COGT), has been granted 17,901 stock options with an exercise price of $31.98 per share and an expiration date of June 9, 2036. These options will vest in full on the earlier of one year from the grant date or the company's 2027 Annual Meeting of Stockholders, contingent on his continued service. This award increases his direct derivative holdings to 17,901 option shares and reflects a compensation-related grant rather than an open-market transaction.
Cogent Biosciences (COGT) director receives 17,901 stock options at $31.98 strike
Cogent Biosciences director Karen Jean Ferrante was granted 17,901 stock options with an exercise price of $31.98 per share, expiring on June 9, 2036. The options will vest fully on the earlier of the first anniversary of the grant date or the company's 2027 Annual Meeting of Stockholders, contingent on her continued service. This transaction is a compensatory award, not an open-market purchase, and increases her direct holdings to 17,901 stock options.
Director for Cogent Biosciences (NASDAQ: COGT) granted 17,901 stock options
Cogent Biosciences director Peter Evan Harwin was granted a stock option for 17,901 shares at an exercise price of $31.98 per share, expiring June 9, 2036. The option vests on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders, contingent on his continued service. Harwin disclaims beneficial ownership as the option is held for investment vehicles managed by Fairmount Funds Management LLC, to whom he must turn over any proceeds.
Cogent Biosciences (COGT) director linked to option grant for funds
Cogent Biosciences director Christopher W. Cain was granted stock options for 17,901 shares at an exercise price of $31.98, expiring on June 9, 2036. These options vest fully upon the earlier of one year from the grant date or the 2027 Annual Meeting of Stockholders, contingent on his continued service. Cain holds these options on behalf of Fairmount Funds Management LLC and disclaims beneficial ownership, as any net proceeds are intended for Fairmount investment funds.
Cogent Biosciences (COGT) director receives 17,901 stock options at $31.98 strike
Matthew Ros, a director at Cogent Biosciences (COGT), was granted 17,901 stock options at an exercise price of $31.98 per share, as detailed in a recent Form 4 filing. These options will vest fully on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders, contingent on his continued service. This transaction represents a compensation grant rather than an open-market purchase or sale.
Assessing Cogent Biosciences (COGT) Valuation After A Strong One Year Run And Cooling Momentum
Cogent Biosciences (COGT) has experienced a strong one-year run but is showing cooling momentum, with recent returns trending lower. Despite analysts targeting a significantly higher price of $54.25 compared to its current $31.16, the company trades at a stretched Price-to-Book ratio of 9.8x, indicating investors are placing a premium on its future pipeline given its clinical stage and reported losses. This valuation is notably higher than industry and peer averages, suggesting strong expectations for its future earnings potential.
Assessing Cogent Biosciences (COGT) Valuation After A Strong One Year Run And Cooling Momentum
Cogent Biosciences (COGT) has seen a strong 1-year performance but recent momentum has cooled, with the stock trading at $31.16 against an analyst target of $54.25. Its Price-to-Book ratio of 9.8x significantly exceeds industry and peer averages, indicating high market expectations for its clinical pipeline despite current losses. The company's valuation is heavily reliant on future prospects and clinical trial success, rather than current financials, posing potential risks if clinical data disappoints.
Cogent Biosciences (COGT) Is Down 7.3% After Priority Review Win For Bezuclastinib Combo In GIST - Has The Bull Case Changed?
Cogent Biosciences (COGT) saw its shares decrease by 7.3% despite its drug, bezuclastinib, receiving Priority Review from the FDA for its combination therapy in GIST patients, setting a PDUFA date for November 30, 2026. This development sharpens the investment narrative for bezuclastinib as a near-term value driver, broadened by new clinical cohorts and expanded access programs. However, the company remains pre-revenue with significant cash burn, raising concerns about potential dilution or refinancing despite its clinical successes.
Cogent Biosciences (COGT) Is Down 7.3% After Priority Review Win For Bezuclastinib Combo In GIST - Has The Bull Case Changed?
Cogent Biosciences (COGT) recently saw its shares decline by 7.3%, despite its drug bezuclastinib receiving Priority Review from the FDA for its combination therapy in GIST. The company presented positive Phase 3 data showing improved progression-free survival, but investors are weighing this against Cogent's significant cash burn and pre-revenue status. The investment narrative is now sharper regarding GIST as a value driver, but funding needs and launch execution risks remain key considerations for the market.
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of...
Cogent Biosciences announced detailed clinical data from its PEAK Phase 3 trial, demonstrating that bezuclastinib in combination with sunitinib significantly improved progression-free survival (PFS) in GIST patients compared to sunitinib alone. The combination therapy achieved a median PFS of 16.5 months versus 9.2 months and was well-tolerated. The company also announced a Priority Review for the bezuclastinib combination by the FDA and the initiation of a new clinical trial for first-line GIST patients.
